SEC Form 4 · accession 0001104659-18-029858
Ra Pharmaceuticals, Inc. · RARX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John C King
Officer — Chief Commercial Officer
Period of report
May 1, 2018
Accepted (ET)
May 2, 2018 · 4:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001481512
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $6.20 | May 1, 2018 | A | 190,000 | A | — | May 1, 2028 | Common Stock | 190,000 | 190,000 | D |
| Restricted Stock UnitsF2,F3 | — | May 1, 2018 | A | 45,987 | A | — | — | Common Stock | 45,987 | 45,987 | D |
Explanation of responses
- F1The stock option vests as to 25% of the underlying shares on April 16, 2019 and as to the remainder of such shares in 36 substantially equal monthly installments upon the reporting person's completion of each successive month of service thereafter, such that the option will become fully vested and exercisable on April 16, 2022.
- F2Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3The restricted stock units vest in three substantially equal installments on each of April 16, 2019, April 16, 2020, and April 16, 2021.